Adaptive Biotechnologies (ADPT) Enterprise Value (2018 - 2025)
Historic Enterprise Value for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to -$213.0 million.
- Adaptive Biotechnologies' Enterprise Value rose 1255.58% to -$213.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.0 million, marking a year-over-year increase of 1255.58%. This contributed to the annual value of -$222.5 million for FY2024, which is 3578.53% up from last year.
- Per Adaptive Biotechnologies' latest filing, its Enterprise Value stood at -$213.0 million for Q3 2025, which was up 1255.58% from -$198.1 million recorded in Q2 2025.
- In the past 5 years, Adaptive Biotechnologies' Enterprise Value registered a high of -$193.6 million during Q1 2025, and its lowest value of -$714.1 million during Q1 2021.
- Its 5-year average for Enterprise Value is -$372.7 million, with a median of -$363.5 million in 2022.
- Per our database at Business Quant, Adaptive Biotechnologies' Enterprise Value soared by 5030.34% in 2021 and then tumbled by 4117.06% in 2022.
- Adaptive Biotechnologies' Enterprise Value (Quarter) stood at -$353.0 million in 2021, then plummeted by 41.17% to -$498.3 million in 2022, then soared by 30.45% to -$346.5 million in 2023, then soared by 35.79% to -$222.5 million in 2024, then rose by 4.3% to -$213.0 million in 2025.
- Its Enterprise Value stands at -$213.0 million for Q3 2025, versus -$198.1 million for Q2 2025 and -$193.6 million for Q1 2025.